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Guidelines
AbstrAct
The full guideline for the investigation and management 
of malignant pleural mesothelioma is published in Thorax. 
The following is a summary of the recommendations 
and good practice points. The sections referred to in the 
summary refer to the full guideline.
IntroductIon
The full guideline for the investigation and 
management of malignant pleural meso-
thelioma is published in Thorax.1 The key 
features of the guideline are highlighted in a 
short article published to accompany the full 
guideline.2 The following is a summary of the 
recommendations and good practice points. 
The sections referred to in the summary refer 
to the full guideline.
bAckground
The key aim of this guideline is to provide 
detailed, evidence-based guidance for the 
investigation of suspected malignant pleural 
mesothelioma (MPM) and the subsequent 
care and management of individuals with 
proven MPM. The main cause of mesothe-
lioma is breathing in asbestos dust—approx-
imately 85% of all male mesotheliomas are 
attributable to occupational asbestos expo-
sure. Products containing asbestos were 
banned in the UK in 1999. The latency 
between first exposure and development 
of the disease is typically 30–40 years. Only 
two-thirds of patients in England and Wales 
receive active anticancer treatment (chemo-
therapy, radiotherapy and surgery) for MPM 
and overall median survival is poor at 9.5 
months, with 1-year and 3-year survival rates 
of only 41% and 12%, respectively. The poor 
survival rates, taken together with the signif-
icant variation in treatment and outcomes 
across the UK, highlight the need for an 
evidence-based guideline to facilitate the 
highest standards of care for all patients with 
mesothelioma in the UK.3
target audience for the guideline
Given the nature of MPM, the majority of the 
guideline will be relevant to secondary care-
based specialists; however, symptom recogni-
tion, management and follow-up are all rele-
vant to community-based specialities.
Intended users include primary care 
general practitioners (GPs) and practice 
nurses; hospital specialist teams in respiratory 
medicine, oncology, thoracic surgery and 
palliative care; hospices/community teams; 
specialist nurses (including lung cancer and 
palliative care); radiologists; pathologists.
Areas covered by the guideline include (1) the 
epidemiology and incidence of mesothelioma 
in the UK and worldwide, (2) the preferred 
investigation pathway of suspected cases of 
MPM, (3) consider special situations including:
•	 Imaging
•	 Histology/cytology
•	 Frail patient not fit for invasive tests
(4) biomarkers, (5) role of mesothelioma 
MDTs, (6) outline best practice in oncolog-
ical management, (7) role of chemotherapy, 
(8) place for radiotherapy, (9) role of surgery, 
(10) guidance on palliation in MPM, (11) 
guidance on providing patients with relevant 
disease-specific information, including medi-
colegal/compensation issues, (12) summary 
of future therapeutic agents that might be 
available within the next 5 years and (13) 
summary of major MPM recommendations.
Non-pleural mesothelioma is excluded 
from this guideline.
Methodology
This guideline is based on the best available 
evidence. The methodology used to write the 
guideline adheres strictly to the criteria as set 
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by the Appraisal of Guidelines, Research and Evaluation 
(AGREE) collaboration, which is available online (www. 
agreetrust. org/ resource- centre/ agree- ii/; The British 
Thoracic Society Standards of Care Committee guide-
line production manual is available at http://www. brit- 
thoracic. org. uk/ guidelines- and- quality- standards/).
clinical questions, literature search and appraisal of the 
literature
Clinical questions were structured in the Patient, Inter-
vention, Control, Outcome format (see online appendix 
1 in the full guideline),1 to define the scope of the guide-
line and inform the literature search. The first search was 
conducted in December 2014 and was updated in July 
2016. Appraisal was performed in line with the AGREE II 
criteria. Further details are available in the full guideline.
considered judgement and grading of evidence
The Guideline Development Group (GDG) used 
evidence tables (see online appendix 2 in the full guide-
line)1 to assess the body of evidence for each clinical ques-
tion. Guideline group members worked in small groups 
to appraise the literature and at least two members of 
each group independently appraised each paper using 
the SIGN critical appraisal checklists. An evidence level 
was assigned to each relevant study using the SIGN meth-
odology (see table 1).
From the outset, it was acknowledged that there would 
be little high-quality evidence for some of the clinical 
questions. Where this was the case, low-grade evidence 
was considered, along with expert opinion via consensus 
at the meetings of the GDG. Parameters were set by the 
GDG when appraising the evidence:
•	 How applicable the obtained evidence was in making 
recommendations for the defined target audience.
•	 Whether the evidence was generalisable and relevant 
to the target population.
•	 Whether there was a clear consistency in the evidence 
used to support recommendations.
•	 What the implications would be on clinical practice in 
terms of resources and skilled expertise.
Cost-effectiveness was not considered in detail as in-depth 
economic analysis of recommendations falls outside of 
the British Thoracic Society (BTS) guideline production 
process. However, the GDG were asked to be mindful of any 
barriers to implementing the recommendations and GPPs.
Recommendations were graded A to D as indicated in 
table 2.
In line with SIGN guidance, ‘minus’ evidence was consid-
ered where necessary, but only in such instances when there 
were no published ‘plus’ papers. In this context, any recom-
mendation based on this evidence was made Grade D. GPPs 
were included where research evidence was lacking, as 
the GDG felt it was important to highlight practical points 
that could improve the care of patients. Research recom-
mendations were also highlighted.
drAftIng the guIdelIne
The GDG was convened in June 2014, with the first meeting 
taking place in October 2014. The group met a total of 
six times and kept in close contact by email and telecon-
ferenced throughout the process. The BTS Standards of 
Care Committee (SOCC) reviewed the draft guideline in 
November 2016. The draft guideline was made available 
online from 22 March 2017 until 24 April 2017 for public 
consultation and circulated to all relevant stakeholders. The 
BTS SOCC reviewed the revised draft in June 2017, and 
final SOCC approval was granted in September 2017.
suMMAry of recoMMendAtIons And good prActIce 
poInts
section 3: clinical features that predict the presence of 
mesothelioma
Recommendations
 ► Do not rule out a diagnosis of MPM on the basis of 
symptoms and examination findings alone. Grade D.
 ► Offer an urgent chest X-ray to patients with symptoms 
and signs as outlined in NICE GL12. Grade D.
 ► Refer all patients with a chest X-ray suggestive of 
MPM urgently (via the 2-week wait suspected cancer 
pathway in England and Wales). Consider referral for 
further investigation in patients with persistent symp-
Table 1 Key to evidence statements
Grade Evidence
1++ High-quality meta-analyses, systematic reviews of RCTs or RCTs with a very low risk of bias
1+ Well-conducted meta-analyses, systematic reviews of RCTs or RCTs with a low risk of bias
1− Meta-analyses, systematic reviews of RCTs or RCTs with a high risk of bias
2++ High-quality systematic reviews of case–control or cohort studies or high-quality case–control or cohort studies with 
a very low risk of confounding, bias or chance and a high probability that the relationship is causal
2+ Well-conducted case–control or cohort studies with a low risk of confounding, bias or chance and a moderate 
probability that the relationship is causal
2− Case–control or cohort studies with a high risk of confounding, bias or chance and a significant risk that the 
relationship is not causal
3 Non-analytic studies, for example, case reports, case series
4 Expert opinion
RCT, randomised controlled trial.
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toms and history of asbestos exposure despite normal 
chest X-ray. Grade D.
 ► A thorough occupational history should be taken to 
cover all occupations throughout life. It is important 
to elicit para exposure by exploring details of relative 
and/or partner occupations. Grade D.
section 4: staging systems
Recommendation
 ► Record staging of MPM according to the version 8 of 
the International Association for the Study of Lung 
Cancer (IASLC) staging proposals. Grade D.
section 5: Imaging modalities for diagnosing and staging
Recommendations
 ► Offer CT thorax with contrast (optimised for pleu-
ral evaluation) as the initial cross-sectional imaging 
modality in the evaluation of patients with suspected 
MPM. Grade D.
 ► Use of PET–CT for aiding diagnosis of MPM is not 
recommended in patients who have had prior talc 
pleurodesis, and caution should be employed in pop-
ulations with a high prevalence of tuberculosis. Grade 
D.
 ► In patients where differentiating T stage will change 
management, consider MRI. Grade D.
 ► In patients where excluding distant metastases will 
change management, offer PET–CT. Grade D.
section 6: pathological diagnosis
Recommendations
 ► Immunohistochemistry is recommended for the dif-
ferential diagnosis of MPM in both biopsy and cytolo-
gy type specimens. Grade D.
 ► A combination of at least two positive mesothelial 
(calretinin, cytokeratin 5/6, Wilms tumour 1, D-240) 
and at least two negative adenocarcinoma immuno-
histochemical markers (TTF1, CEA, Ber-EP4) should 
be used in the differential diagnosis of MPM. (Markers 
listed in likely order of value). Grade D.
 ► Do not rely on cytology alone to make a diagnosis of 
MPM unless biopsy is not possible or not required to 
determine treatment due to patient wishes or poor 
performance status. Grade D.
 ► Pathologists should report the histological subtype of 
MPM in all cases. Grade D.
Good practice points
 ✔ Biopsies from patients with suspected MPM should be 
reviewed by a pathologist experienced in the diagno-
sis of MPM, and a second opinion should be sought if 
there is uncertainty over the diagnosis.
section 7: use of biomarkers
Recommendations
 ► Do not offer biomarkers in isolation as a diagnostic 
test in MPM. Grade B.
 ► Consider biomarker testing in patients with suspi-
cious cytology who are not fit enough for more inva-
sive diagnostic tests. Grade B.
 ► Do not routinely offer biomarker testing to predict 
treatment response or survival. Grade B.
 ► Do not offer biomarker testing to screen for MPM. 
Grade C.
Research recommendation
Further research is required to identify biomarkers that reli-
ably predict treatment response within clinical practice.
section 8: factors determining prognosis and timing of 
treatment
Recommendations
 ► Consider calculating a prognostic score in patients 
with MPM at diagnosis. Grade D.
 ► Prognostic scores can provide useful survival informa-
tion for patients and doctors but should not be used 
in treatment decision-making. Grade D.
Table 2 Grades of recommendations
Grade Type of evidence
A At least one meta-analysis, systematic review, or RCT rated as 1++ and directly applicable to the target population 
or
A systematic review of RCTs or a body of evidence consisting principally of studies rated as 1+ directly applicable to 
the target population and demonstrating overall consistency of results
B A body of evidence including studies rated as 2++ directly applicable to the target population and demonstrating 
overall consistency of results or
Extrapolated evidence from studies rated as 1++ or 1+
C A body of evidence including studies rated as 2+ directly applicable to the target population and demonstrating 
overall consistency of results or
Extrapolated evidence from studies rated as 2++
D Evidence level 3 or 4 or
Extrapolated evidence from studies rated as 2+
√ Important practical points for which there is no research evidence, nor is there likely to be any research evidence. 
The guideline committee wishes to emphasise these as Good Practice Points.
RCT, randomised controlled trial.
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 ► When calculating a prognostic score, use one of the 
following:
a. The EORTC prognostic score
b. The CALGB score
c. The modified Glasgow Prognostic Score
d. The LENT score if a pleural effusion is present
e. The decision tree analysis
The decision tree analysis scoring systems is likely to 
be the most useful in routine clinical practice. Grade D.
section 9: pleural fluid management
Recommendations
 ► Offer either talc (via slurry or poudrage) or indwell-
ing pleural catheters for symptomatic pleural effusion 
in MPM, informed by patient choice. Grade A.
 ► Talc slurry or thoracoscopic talc poudrage pleurode-
sis should be offered to patients with MPM in prefer-
ence to a video-assisted thoracoscopic surgery partial 
pleurectomy (VATS-PP) surgical approach for fluid 
control in MPM. Grade A.
section 10: the role of surgery
Recommendations
 ► Do not offer VATS-PP over talc pleurodesis in MPM. 
Grade A.
 ► Do not offer extra-pleural  pneumonectomy (EPP) in 
MPM. Grade B.
 ► Do not offer extended pleurectomy decortication 
(EPD) outside of a clinical trial. Grade D.
Research recommendation
The role of VATS-PP and EPD in good prognosis patients 
should be examined further in clinical trials, which 
should include robust measurement of quality of life.
section 11: systemic anticancer treatment
Recommendations
 ► Offer patients with MPM with good performance sta-
tus (WHO 0–1) first-line therapy with cisplatin and 
pemetrexed. Where licensed (not presently in the 
UK), bevacizumab should be added to this regime. 
Raltitrexed is an alternative to pemetrexed. Grade 
A.
 ► Do not offer pemetrexed or vorinostat as second-line 
treatment for patients with MPM. Grade A.
Good practice points
 ✔ Where cisplatin is contraindicated, or has adverse risk, 
offer carboplatin in combination with pemetrexed.
 ✔ First-line clinical trials are an appropriate option for 
patients with good performance status and are rec-
ommended above any other option for second-line 
treatment, providing the patient is of adequate per-
formance status.
Research recommendations
The role of immunotherapy in MPM should be further 
assessed in large phase III randomised controlled trials.
Further randomised controlled trials of second-line 
therapy on MPM are required.
section 12: radiotherapy
Recommendations
 ► Do not offer prophylactic radiotherapy to chest wall 
procedure tracts routinely. Grade A.
 ► Do not offer preoperative or postoperative radiother-
apy in MPM. Grade A.
 ► Do not offer hemithorax radiotherapy for MPM. 
Grade D.
 ► Consider palliative radiotherapy for localised pain in 
MPM where the pain distribution matches areas of 
underlying disease. Grade D.
Research recommendation
Prospective clinical trials of preoperative radiotherapy, 
postoperative radiotherapy after pleurectomy decortica-
tion and definitive radiotherapy after chemotherapy in 
MPM are required.
Further prospective randomised clinical trials 
are required to determine the role of radiotherapy 
for symptom control in MPM and the optimal dose 
fractionation.
section 13: symptom control
Good practice point
 ✔ Symptoms in MPM should be managed as per cur-
rent guidelines for cancer in general (see section 13: 
symptom control in the full guideline) and early in-
volvement of palliative care specialists is recommend-
ed.
section 14: care and management
Recommendation
 ► Consider referring MPM cases to a regional mesothe-
lioma MDT. Grade D.
 ► Offer accurate and understandable information to 
patients and carers about compensation for MPM. 
Grade D.
 ► Offer patients with MPM and their carers the oppor-
tunity to discuss concerns regarding their disease. 
Grade D.
 ► In patients with MPM where accurate determination 
of radiological progression is required, consider CT 
with modified Response Evaluation Criteria in Solid 
Tumours (mRECIST) measurement. Grade D.
Good practice points
 ✔ All mesothelioma cases should be discussed in a time-
ly fashion by a MDT that reviews a sufficient number 
of cases to maintain expertise and competence in the 
diagnosis and treatment of MPM.
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 ✔ The MDT membership should fulfil the require-
ments set by national cancer peer review (to include a 
named clinical nurse specialist for MPM).
 ✔ The MDT should maintain an up-to-date portfolio of 
mesothelioma trials and offer recruitment to all eligi-
ble patients.
 ✔ A personalised care approach should be considered 
for each patient.
Patients should be offered 3–4 monthly follow-up 
appointments with an oncologist, respiratory physician or 
specialist nurse according to their current treatment plan. 
If patients wish to be seen less frequently, offer regular 
telephone follow-up with specialist nurse with an option 
to attend clinic in the event of clinical deterioration. 
 
Healthcare providers need to use clinical judgement, knowledge and 
expertise when deciding whether it is appropriate to apply recom-
mendations for the management of patients. The recommendations 
presented here are a guide and may not be appropriate for use in 
all situations. The guidance provided does not override the responsi-
bility of healthcare professionals to make decisions appropriate to the 
circumstances of each patient, in consultation with the patient and/or 
their guardian or carer.
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